The proposed move marks a significant step in Siemens’ ongoing strategic realignment, as the company looks to reduce its exposure to the healthcare sector and sharpen its focus on core industrial and digital businesses.
According to the company, preparations for the separation are already well underway. Both the structural and regulatory processes have made substantial progress, although final regulatory clearance is still pending. Once approved, Siemens shareholders will receive shares in Siemens Healthineers directly, effectively redistributing part of Siemens’ holdings in the subsidiary.
Siemens currently owns about 67 percent of Siemens Healthineers. Under the proposed plan, it intends to transfer roughly 30 percent of that stake to its shareholders. This would significantly dilute Siemens’ ownership and result in the company relinquishing its majority control of the healthcare business.
The plan builds on an earlier announcement made in November, when Siemens first revealed the multi-billion-euro transaction. At the time, the company had considered convening an Extraordinary General Meeting in 2026 to approve the spin-off, but has now opted to bring the decision to its regular shareholder meeting in 2027.
In a statement, Siemens reiterated that while the separation and regulatory clarification processes are well advanced, final confirmation from regulators remains outstanding.
The move also reflects a broader shift in Siemens’ corporate strategy. The company has indicated that medical technology—including products such as X-ray systems and laboratory diagnostics—is no longer central to its long-term business focus.
Siemens Healthineers AG itself has operated with a degree of independence since it was listed on the stock market in 2018. However, Siemens retained a controlling stake until now, maintaining significant influence over its operations.
If approved, the planned spin-off would mark a decisive break, allowing Siemens Healthineers to operate with greater autonomy while giving Siemens shareholders direct ownership in the healthcare company.
The outcome of the February 2027 vote will determine the final structure of the separation, as investors weigh the potential benefits of a more focused Siemens against the opportunities presented by direct stakes in a global medical technology leader.